|
|
Article: Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents.
- Article from:
- PR Newswire
- Article date:
- August 19, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte filed a joint patent application identifying a biomarker, present in many common cancers, that is a target of drugs being evaluated by Lixte and NINDS for the treatment of brain tumors.
Dr. John S. Kovach, President and CEO of Lixte, said, "Studies with the research team at the Molecular Pathogenesis Unit, Surgical Neurology Branch, NINDS, identified a biomarker that appears to be preferentially targeted by novel ...